The innovative development of Russian pharmaceuticals, intellectual property protection, and state support measures for the industry will be key discussion topics at the session ‘Pharma: New Aspects of International Cooperation’ during the BIOPROM 2025 international forum in Gelendzhik held on October 6-7. Details were shared by Vadim Kukava, Executive Director of the Pharmaceutical Innovations Association (‘Infarma’) and one of the session organizers. A regular BIOPROM participant, Infarma unites major drug manufacturers ranked among the global top 20, all actively investing in R&D.
As Kukava noted, a primary goal of innovative drug development is to extend healthy lifespans and improve wellbeing, particularly for aging populations, a critical priority amid Russia’s demographic shifts and rising median age.
International collaboration remains vital: "Despite geopolitical challenges," stressed Infarma’s Executive Director, "foreign partners continue localizing production and investing in research, ensuring access to over 50% of high-tech medications by value."
Kukava emphasized BIOPROM’s unique advantage as a platform for direct dialogue among top experts, regulators, manufacturers, and researchers. Large-scale discussions involving businesses will yield concrete solutions to elevate Russia’s pharmaсeutical industry to a whole new level.
As Kukava noted, a primary goal of innovative drug development is to extend healthy lifespans and improve wellbeing, particularly for aging populations, a critical priority amid Russia’s demographic shifts and rising median age.
International collaboration remains vital: "Despite geopolitical challenges," stressed Infarma’s Executive Director, "foreign partners continue localizing production and investing in research, ensuring access to over 50% of high-tech medications by value."
Kukava emphasized BIOPROM’s unique advantage as a platform for direct dialogue among top experts, regulators, manufacturers, and researchers. Large-scale discussions involving businesses will yield concrete solutions to elevate Russia’s pharmaсeutical industry to a whole new level.